Structured evidence table for Bergamot Blood Pressure Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Bergamot Blood Pressure Randomized Trial | Background Subsyndromal generalized anxiety is highly prevalent and associated with impaired well-being, elevated stress, and functional limitations, yet affected individuals often do not meet criteria for guideline-based treatment. | 2 | Ngandeu Schepanski S (2026) | Essential Oil-enhanced digital hypnotherapy for subclinical generalized anxiety: a study protocol for a randomized controlled trial. |
| Bergamot Blood Pressure Randomized Trial | Discussion This study is expected to provide evidence on the efficacy of essential oil-enhanced digital hypnosis for subsyndromal anxiety and will examine whether repeated pairing of hypnosis and olfactory stimulation induces conditioned relaxation responses. | 2 | Ngandeu Schepanski S (2026) | Essential Oil-enhanced digital hypnotherapy for subclinical generalized anxiety: a study protocol for a randomized controlled trial. |
| Bergamot Blood Pressure Randomized Trial | If effective, this multimodal, low-intensity intervention could represent a scalable preventive approach for individuals with increased anxiety who are not receiving formal treatment and have been medically diagnosed. | 2 | Ngandeu Schepanski S (2026) | Essential Oil-enhanced digital hypnotherapy for subclinical generalized anxiety: a study protocol for a randomized controlled trial. |
| Bergamot Blood Pressure Randomized Trial | Scalable, low-threshold digital interventions that target psychophysiological regulation may help address this gap. | 2 | Ngandeu Schepanski S (2026) | Essential Oil-enhanced digital hypnotherapy for subclinical generalized anxiety: a study protocol for a randomized controlled trial. |
| Bergamot Blood Pressure Randomized Trial | Epidemiological studies indicate that CRS affects a substantial proportion of patients, with an estimated prevalence of up to 0.4% in the general population and 2–3% in individuals with diabetes and heart failure, and is associated with increased morbidity and mortality [,]. | 3 | Carollo Caterina (2026) | Nature’s Bioactives in Cardiorenal Syndrome: Polyphenols at the Crossroads—Preclinical Insights into Redox, Inflammation, and Mitochondrial Protection |
| Bergamot Blood Pressure Randomized Trial | Most preclinical studies investigating polyphenolic interventions have focused on type IV and type V CRS, particularly diabetes-induced chronic kidney disease with associated cardiovascular dysfunction [,]. | 3 | Carollo Caterina (2026) | Nature’s Bioactives in Cardiorenal Syndrome: Polyphenols at the Crossroads—Preclinical Insights into Redox, Inflammation, and Mitochondrial Protection |
| Bergamot Blood Pressure Randomized Trial | Specifically, gut dysbiosis leads to an increased intestinal permeability (leaky gut), allowing the translocation of microbiota-derived uremic toxins (such as p-cresyl sulfate and TMAO) into the systemic circulation [,]. | 3 | Carollo Caterina (2026) | Nature’s Bioactives in Cardiorenal Syndrome: Polyphenols at the Crossroads—Preclinical Insights into Redox, Inflammation, and Mitochondrial Protection |
| Bergamot Blood Pressure Randomized Trial | 1 2 3 4 5 6 7 1 2 1 2 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 Figure 1 Cardiorenal syndromes (CRS) describe the complex bidirectional interaction between the heart and the kidneys, whereby acute or chronic dysfunction of one organ induces structural and functional impairment of the other []. | 3 | Carollo Caterina (2026) | Nature’s Bioactives in Cardiorenal Syndrome: Polyphenols at the Crossroads—Preclinical Insights into Redox, Inflammation, and Mitochondrial Protection |
Source documents